FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Elli Novatcheva, Yasmine Anouty, Ila M. Saunders, James K. Mangan, Aaron M. Goodman
Abstract
FLT3 inhibitors are promising new molecular therapeutics increasingly becoming standard of care for both newly diagnosed and relapsed/refractory FLT3 positive AML. This review will focus on the clinical trials/evidence, similarities, differences, clinical toxicities, and drug interactions relevant to treating clinicians as pertains to 5 FLT3-inhibitors: midostaurin, sorafenib, gilteritinib, crenolanib, and quizartinib.
Topics & Concepts
Myeloid leukemiaSorafenibMidostaurinMedicineTyrosine kinaseCancer researchTyrosine-kinase inhibitorOncologyCD135LeukemiaNPM1Fms-Like Tyrosine Kinase 3Receptor tyrosine kinaseInternal medicineCancerBiologyMutationReceptorGeneKaryotypeBiochemistryHepatocellular carcinomaChromosomeAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment